

Your support is lighting the way for life-changing liver cancer research

A future of hope, built on collaboration

Every year, more than 200 Western Australians are diagnosed with primary liver cancer – and most face a prognosis of just 12 months.

That's why Charlies Foundation for Research is proud to support the Liver Cancer Collaborative (LCC) – a groundbreaking, multidisciplinary WA-led alliance bringing together researchers, clinicians, and data scientists across Curtin University, Harry Perkins Institute of Medical Research, and the University of Western Australia, and Sir Charles Gairdner, Royal Perth and Fiona Stanley hospitals. Together, they're transforming how liver cancer is understood and treated through a bold, collaborative vision.

At the heart of this work is Clinical A/Prof Michael Wallace, Consultant Hepatologist and Clinical Lead of the LCC. With your support, his team, in partnership with the Perkins Cancer Biobank, has built a powerful collection of tissue and blood samples from hundreds of patients across all stages of disease. These samples are helping decode the complex genetic drivers of liver cancer, laying the groundwork for more targeted, personalised treatment options.

"We're on a world-first journey to create a clinical tool that helps doctors choose the best treatment for each individual patient – giving them a better chance at life."

– Clinical A/Prof Michael Wallace




From left: Louise Winteringham (LCC Program Manager), Nina Tirnitz-Parker (LCC Co-Director), Michael Wallace (LCC Clinical Lead), Peter Leedman (LCC Co-Director).

Tiny organs making a big impact

That future is already taking shape in the lab of Dr Ben Dwyer at Curtin University, where researchers are growing miniature livers – known as organoids – from patients' own cells. These tiny 3D replicas mimic tumour behaviour and allow researchers to test how each responds to different treatments.

“Organoids offer a powerful tool to study resistance and personalise therapy. It’s about finding the right treatment, for the right person, at the right time.” – Dr Ben Dwyer

Together, the biobank and organoid platform represent the future of precision cancer care – driven by Western Australian expertise and powered by donor generosity.



Thank you for helping to make world-class research like this possible. Your support is creating a future where liver cancer patients have better options, better treatments, and renewed hope.



Associate Professor Michael Wallace, Clinical Lead at the groundbreaking Liver Cancer Collaborative.